The US FDA has awarded Fast Track Designation to Israeli biotech Galmed for its Aramchol treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  Galmed is to perform Phase IIb trials of Aramchol this year with 240 NASH patients who also suffer from obesity and insulin resistance.

http://www.globes.co.il/en/article-galmed-jumps-on-fda-hepatitis-drug-approval-1000974455